These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 34311075)

  • 1. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.
    Loi S; Michiels S; Adams S; Loibl S; Budczies J; Denkert C; Salgado R
    Ann Oncol; 2021 Oct; 32(10):1236-1244. PubMed ID: 34311075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC).
    Blackley EF; Loi S
    Breast; 2019 Nov; 48 Suppl 1():S44-S48. PubMed ID: 31839159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.
    Gonzalez-Ericsson PI; Stovgaard ES; Sua LF; Reisenbichler E; Kos Z; Carter JM; Michiels S; Le Quesne J; Nielsen TO; Laenkholm AV; Fox SB; Adam J; Bartlett JM; Rimm DL; Quinn C; Peeters D; Dieci MV; Vincent-Salomon A; Cree I; Hida AI; Balko JM; Haynes HR; Frahm I; Acosta-Haab G; Balancin M; Bellolio E; Yang W; Kirtani P; Sugie T; Ehinger A; Castaneda CA; Kok M; McArthur H; Siziopikou K; Badve S; Fineberg S; Gown A; Viale G; Schnitt SJ; Pruneri G; Penault-Llorca F; Hewitt S; Thompson EA; Allison KH; Symmans WF; Bellizzi AM; Brogi E; Moore DA; Larsimont D; Dillon DA; Lazar A; Lien H; Goetz MP; Broeckx G; El Bairi K; Harbeck N; Cimino-Mathews A; Sotiriou C; Adams S; Liu SW; Loibl S; Chen IC; Lakhani SR; Juco JW; Denkert C; Blackley EF; Demaria S; Leon-Ferre R; Gluz O; Zardavas D; Emancipator K; Ely S; Loi S; Salgado R; Sanders M;
    J Pathol; 2020 Apr; 250(5):667-684. PubMed ID: 32129476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Characteristics of Lymphocyte-predominant Triple-negative Breast Cancer.
    Sasaki R; Horimoto Y; Yanai Y; Kurisaki-Arakawa A; Arakawa A; Nakai K; Saito M; Saito T
    Anticancer Res; 2021 Apr; 41(4):2133-2140. PubMed ID: 33813424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
    Sarradin V; Lusque A; Filleron T; Dalenc F; Franchet C
    Breast Cancer Res; 2021 May; 23(1):61. PubMed ID: 34039396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer.
    Wang H; Ding XH; Liu CL; Xiao Y; Shui RH; Li YP; Chen C; Yang WT; Liu S; Chen CS; Shao ZM; Jiang YZ
    J Natl Cancer Inst; 2023 Dec; 115(12):1586-1596. PubMed ID: 37549066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
    Loi S; Dushyanthen S; Beavis PA; Salgado R; Denkert C; Savas P; Combs S; Rimm DL; Giltnane JM; Estrada MV; Sánchez V; Sanders ME; Cook RS; Pilkinton MA; Mallal SA; Wang K; Miller VA; Stephens PJ; Yelensky R; Doimi FD; Gómez H; Ryzhov SV; Darcy PK; Arteaga CL; Balko JM
    Clin Cancer Res; 2016 Mar; 22(6):1499-509. PubMed ID: 26515496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of immune checkpoints expression and lymphocyte densities of iranian breast cancer patients; the co-expression status and clinicopathological associates.
    Pournabee M; Keshavarz-Fathi M; Esmaeili P; Mahdavi Sharif P; Nili F; Jahanbin B
    BMC Cancer; 2023 Jun; 23(1):495. PubMed ID: 37264298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
    Uğurluoğlu C; Yormaz S
    Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes.
    Ni Y; Tsang JY; Shao Y; Poon IK; Tam F; Shea KH; Tse GM
    Oncologist; 2022 Apr; 27(4):e313-e327. PubMed ID: 35380716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
    Dieci MV; Mathieu MC; Guarneri V; Conte P; Delaloge S; Andre F; Goubar A
    Ann Oncol; 2015 Aug; 26(8):1698-704. PubMed ID: 25995301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
    Agahozo MC; van Bockstal MR; Groenendijk FH; van den Bosch TPP; Westenend PJ; van Deurzen CHM
    Mod Pathol; 2020 Feb; 33(2):196-205. PubMed ID: 31375764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases.
    Voutilainen S; Heikkilä P; Bartkova J; Nevanlinna H; Blomqvist C; Bartek J; Mattson J
    BMC Cancer; 2022 Dec; 22(1):1298. PubMed ID: 36503417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis-related novel immunostaining pattern for programmed cell death ligand 1 and prognostic value of tumour-infiltrating lymphocytes in triple-negative breast cancer.
    Savaş P; Serin G; Gürsoy P; Zekioğlu O; Özdemir N
    Pol J Pathol; 2023; 74(2):65-74. PubMed ID: 37728465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.